SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
沐浠
Lv3
370 积分
2024-01-31 加入
最近求助
最近应助
互助留言
The Cost-Effectiveness of Pertuzumab for the Treatment of Metastatic HER2+ Breast Cancer in Czechia: A Semi-Markov Model Using Cost States
1个月前
已完结
Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer
1个月前
已完结
FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer
1个月前
已完结
Patients value metastatic cancer therapy more highly than is typically shown through traditional estimates
2个月前
已关闭
Economic evaluations of first-line chemotherapy regimens for pancreatic cancer: a critical review
2个月前
已完结
Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer
2个月前
已完结
S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial
2个月前
已完结
A primitive Y chromosome in papaya marks incipient sex chromosome evolution
2个月前
已关闭
Effectiveness, safety and cost of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world data analysis
2个月前
已完结
Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study
2个月前
已完结
没有进行任何应助
感谢
1个月前
感谢
1个月前
感谢
1个月前
感谢
2个月前
感谢
2个月前
更改不了题目【积分已退回】
2个月前
标题错误。正确的题目应为 S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial. Expert Rev Pharmacoecon Outcomes Res. 于2020年发表。
2个月前
感谢
2个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论